St. Jude expands European TAVI trial to include larger valves

February 4, 2013 by MassDevice staff

St. Jude Medical expands a European transcatheter aortic valve implantation study to include a larger 25 mm valve in treatment of patients with severe aortic stenosis.

St. Jude Medical's Portico heart valve

St. Jude Medical (NYSE:STJ) researchers implanted the 1st patient with a larger-sized Portico transcatheter aortic valve as part of the medical device maker's ongoing Portico TF EU trial.

The trial was launched to evaluate the 23 mm valve and has been expanded to include the 25 mm valve as well. The data from the study will support a bid for European regulatory approval for the Portico valve, according to a press release.

Sign up to get our free newsletters delivered right to your inbox.

St. Jude plans to implant up to 50 patients in the 25 mm arm of the trial, which cardiovascular & ablation technologies president Frank Callaghan called "another major milestone" for the company's TAVI program.